The interplay between metastasising cancer cells and immunotherapy

Speaker: Dr. Joachim Fluhrer

 Dr. Joachim Fluhrer

Dr. Joachim Fluhrer

Topics include

  • Immune system and inflammation in oncogenomics
  • Natural Killer cells in cancer and immunotherapy
  • Downregulated CTCs and CTC fragments as markers of immune activity

Monday 26th March 4pm AEST (6pm NZST)
Tuesday 27th March 6pm AEST (8pm NZST)


    The resistance mechanisms of tumour cells are now a focus of Oncology research laboratories and clinics across the globe. Despite surgery, chemotherapeutic treatment and ionizing radiation, cancers can spread or relapse, and it is this metastatic progression that is primarily responsible for the majority of cancer-related deaths.

    The last decade has seen a burgeoning of research and interest in the harnessing the role of the immune system in the treatment cancer.  Both the innate and adaptive immune systems play a critical role in preventing the development of neoplastic disease in a process called 'immunosurveillance.' When the immune system is functioning well, tumour cells are eliminated. When the immune response is inadequate, tumour growth and immunosurveillance enter a tug-of-war until a tumour cell mutates to evade surveillance and proliferates. 

    Recent advances in understanding the biology of Natural Killer (NK) cells has generated enormous interest in their clinical utility. NK cells possess powerful anti-tumour mechanisms that show great potential in counteracting the a tumour's evasion of the immune system.

    Circulating Tumour Cells are the metastasising population of cancer cells that have mutated to allow migration into the bloodstream. The dynamics of these cells as indicators of treatment response and metastatic potential has been repeatedly demonstrated. The most aggressive of these cells are able to evade the immune system and may eventuate in metastatic growth. Knowledge of the immunogenicity of these cells and their interplay with Natural Killer cells represent a new point of conversion between the prevention of tumour progression and immunotherapy.


    Name *
    This is to ensure practitioner-only attendance
    All practitioners are welcome to attend the webinar that most suits them.


    Genostics KYO II Cancer Seminar 2017 - Video recording (available for pre-order)

    Saturday 11th & Sunday 12th November, 2017
    Four Seasons, Sydney

    The seminar focused on currently available options for personalised diagnostics and the effective monitoring of a person's cancer in real time, as well as presented additional treatment strategies that may arise from personalised diagnostics.

    Click here to download full seminar brochure
    Click here to view lecture timetable

    Video recording + lecture slides are available for pre-order and will be available soon.
    Please note, to ensure patient confidentiality, some lectures/slides will not be distributed.
    Price: $95 (+gst)

    Add To Cart





     December Seminar

    December Seminar

    CTC Seminar:

    Monitoring the effectiveness of cancer treatment

    A joint-seminar with Dr. Katherina Pachmann and Dr. Fluhrer

    Practitioners are invited to join practitioners at the Genostics CTC Seminar designed to bring you the latest information on how to monitor the effectiveness of cancer treatment, presented by world-renowned CTC scientist Prof. Katherina PachmannThe Seminar

    Circulating Tumour Cells (CTCs) are the metastasising population of cancer cells. CTCs are now well established as independent prognostic indicators of metastatic disease. CTC enumeration and analysis represents a 'fluid-biopsy,' with results now firmly associated with clinical outcome. Practitioners and Oncologists who are interested or are already benefiting from using CTC-tests will be in attendance.

    Prof. Katherina Pachmann is a world-renowned expert in Circulating Tumour Cell science - both in research and in translational medicine. She has worked internationally in academically and scientifically acclaimed cell research centers. She will be presenting new research at COSA and the World Cancer Congress in November in Melbourne, as well as presenting seminars to practitioners in locations around Australia and New Zealand.

    Dr. Joachim Fluhrer has recently been acknowledged internationally for Excellence in Integrative Medicine, and will be touring alongside Prof. Pachmann. Dr. Fluhrer brings his clinical and medical expertise to the discussion table, and is passionate about facilitating the best in evidence-based medical research for use in the clinical setting.

    This seminar will be a unique opportunity to meet CTC expert scientist Prof. Pachmann and discuss clinical cases you might have with her and Dr. Fluhrer together. The seminar will include updates on the latest in CTC-technology and how it is revolutionising cancer monitoring, and will be a great chance to meet and discuss personalised cancer treatment with colleagues.

    CTC Characterisation is expected to contribute to guiding specific targeted therapies to a defined population of cancer patients within a certain therapeutic window - which is the hallmark of personalized medicine
    — Alix-Panabieres & Pantel, Clinical Chemistry 2014, 59(1): 110-8

    More info.. Professor Pachmann has concentrated her research career on the detection, identification, and treatment of cancer cells in the peripheral blood. Professor Pachmann has worked in cell research internationally in academically and scientifically acclaimed centres such as Karolinka Insitute Stockholm, Sweden; Institute of Hematology,GSF Munich, Germany; MD Anderson Cancer Centre Houston, Texas.


    Presently Professor Pachmann has her laboratory at the Klinik fur Innere Medizin II Fredrich-Schiller Universitat in Germany, where she holds Professorship Experimental Hematology and Oncology. Professor Pachmann has numerous publications in world renowned journals of Hematology, Clinical Oncology, Surgical Oncology and Cancer Research.


    CTC Webinar Series

    Presented by Dr Joachim Fluhrer

    Level I: (Completed)
    Metastatic biology, Circulating Tumour Cells and personalised cancer management

    Level II: (Completed)
    In the clinic: monitoring treatment effectiveness and metastatic risk, CTC test selection and report interpretation

    Level III: (Completed)
    Clinical Case Discussions: practitioner presentations